• Tivozanib (AV-951): Evidence and Research Context

  2026-10-06

  Tivozanib (AV-951) is a selective VEGFR-targeting tyrosine kinase inhibitor studied in anti-angiogenic oncology, especially renal cell carcinoma. This overview compares biochemical, cellular, preclinical, clinical, and assay-method evidence while distinguishing supplier-reported claims from findings supported by the supplied dissertation. It also explains why proliferation, viability, and cell-death endpoints should not be treated as interchangeable.

• Telatinib (BAY 57-9352): From Targets to Translation

  2026-10-05

  A source-grounded analysis of Telatinib (BAY 57-9352) as a multitarget kinase probe, interpreting recent triple-negative breast cancer findings while defining the evidence needed for stronger translational claims.

• D-Mannitol B2090: Product Overview

  2026-10-05

  D-Mannitol B2090 is a supplier-described biochemical reagent for conceptual osmotic regulation research, renal function studies, and diuretic mechanism investigation. No matched paper evidence was provided.

• Syringin Enhances Sunitinib in Renal Cell Carcinoma

  2026-10-04

  A 2024 Journal of Functional Foods study investigated syringin as a natural-product candidate for renal cell carcinoma and examined whether it could increase cellular sensitivity to Sunitinib. Its computational and cell-based evidence connects the response to EGFR/PI3K/Akt signaling, while the absence of clinical and in vivo validation limits conclusions about therapeutic translation.

• Caged Bioluminescent Probe for Immunoproteasome

  2026-10-03

  Loy and Trader describe a cleavable, immunoproteasome-selective activity-based probe that couples peptide recognition with an aminoluciferin bioluminescent reporter. The protocol supports luminescent measurement of immunoproteasome activity in cellular assays and provides a foundation for studying disease-associated proteasome function, while leaving in vivo validation as future work.

• DOPE in Lipid Delivery: From Fusion to Assay Design

  2026-10-02

  Explore how 1,2-Dioleoyl-sn-glycero-3-PE (DOPE) governs membrane behavior in nucleic acid delivery and how lipidomics can sharpen assay interpretation. This article connects formulation controls with the 2024 Magnaporthe oryzae study without treating distinct biological systems as equivalent.

• PD 173074: FGFR1 Assay Workflows

  2026-10-01

  PD 173074 enables dose-tiered dissection of FGFR1 and VEGFR2 signaling in kinase, cell, and angiogenesis models. This guide converts its ATP-competitive mechanism into practical workflows, controls, and troubleshooting strategies for cancer research and vascular biology.

• Biotin-Tyramide: From Signal Gain to Spatial Insight

  2026-10-01

  A mechanistic and translational guide to Biotin-tyramide, explaining how HRP-driven biotin deposition converts molecular recognition into high-resolution signal amplification for IHC, ISH, and emerging biosensing workflows.

• Pazopanib Hydrochloride: From Kinase Maps to Response

  2026-09-30

  A translational framework for using Pazopanib Hydrochloride and GW786034 to connect multi-target kinase biology with more rigorous cancer-response measurements, especially in renal cell carcinoma and soft tissue sarcoma research.

• Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT

  2026-09-30

  This 2024 Journal of Ethnopharmacology study integrates network pharmacology with cellular and mouse experiments to investigate how Shenqi Fuzheng injection affects glioma growth and migration. Its central contribution is a cautiously supported link between SFI activity and SRC/PI3K/AKT signaling, accompanied by evidence of cell-cycle arrest, reduced migration-associated phenotypes, and slower tumor development.

• Sunitinib: Phosphoproteomic Assay Strategy

  2026-09-29

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with applications spanning angiogenesis, apoptosis, and cell-cycle research. This article uses a landmark Zika phosphoproteome study to develop a phosphosite-aware strategy for designing and interpreting Sunitinib experiments.

• Thioguanine Workflows for Cancer and EV71 Studies

  2026-09-29

  Thioguanine supports a unified workflow for cancer cell proliferation inhibition, epigenetic profiling, and EV71 virus inhibition, while its formulation requires careful DMSO handling. This practical guide connects benchmark activity with MIR9-centered acute lymphoblastic leukemia research and provides assay-ready optimization and troubleshooting advice.

• MG-262: Reversible Proteasome Inhibitor Guide

  2026-09-28

  MG-262, also called Z-Leu-Leu-Leu-B(OH)2, is a cell-permeable, reversible inhibitor of proteasome chymotryptic activity. It supports proteasome inhibition assay design, apoptosis research, and mechanistic studies of ubiquitin-dependent proteostasis, but it does not by itself establish a treatment for age-related muscle disease.

• ATRX Loss and RTK Inhibitor Sensitivity in Glioma

  2026-09-28

  Pladevall-Morera and colleagues report that ATRX-deficient high-grade glioma cells are more sensitive to several receptor tyrosine kinase and PDGFR inhibitors, with additional toxicity when RTK inhibition is combined with temozolomide. The findings support considering ATRX status in preclinical studies and clinical-trial analyses, while leaving the responsible receptor dependencies and clinical benefit to be established.

• Neuromedin S (rat): Handling and Assay Guide

  2026-09-27

  Neuromedin S (rat) provides a defined peptide ligand for controlled investigation of neuromedin U receptor signaling and GPCR/G protein responses. This guide covers preparation and assay controls; the reagent is for scientific research only and does not establish potency, therapeutic value, or performance in clinical or cross-species applications.

8390 records 1/560 page Next 12345 下5页 Last page